EANS-News: november AG
The positive trend of the november AG continues through
the 3rd quarter
Cologne (euro adhoc) -
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.
quarterly report/Company Information
Publication of consolidated quarterly report per September 30, 2009
- The operating profit of PROGEN Biotechnik GmbH shows a remarkable increase to TEUR 800 - Consolidated operating results increased to TEUR 2.925 as compared to TEUR 195 in 2008 - Liquidity increased 41% as compared to December 31, 2008 - Successful implementation of restructuring of financial obligations and capital - Earning per share (EPS) EUR 0.62
The quarterly financial report as of September 30, 2009 indicates that the november group, mainly consisting of the november AG (holding company) and the operative business units PROGEN Biotechnik GmbH and Multimetrix GmbH, could increase the operative results to TEUR 3.003 (2008 TEUR -274), despite the slow market and economic crisis. During the first nine months of 2009 considerably increased consolidated results of TEUR 2.925 (2008 TEUR 195) were achieved. Major reason for this is the very positive development of the operating results of PROGEN Biotechnik GmbH with roughly TEUR 800, the financial settlement and compensatory payment of AXIS-Shield GmbH and the interest and loan waiver by the investors. Operating results of PROGEN Biotechnik GmbH could have been even TEUR 200 higher if it were not for liabilities resulting from an arbitration settlement in a patent case. Consolidated sales revenues are slightly below last year´s figures due to the fact that sales rights and products were transferred by the subsidiary PROGEN Biotechnik GmbH to AXIS-Shield. However, the extreme decrease in cost of materials justifies the strategic decision to abandon this unprofitable business segment. The liquidity of the november group at September 30, 2009 is a remarkable TEUR 822, resulting from the purchase price for the sale of holdings in the identif GmbH in the amount of TEUR 665 as well as the compensatory payment of AXIS-Shield GmbH of TEUR 1.000. From this compensation, another TEUR 200 will be received beginning of year 2010. As already reported in previous ad-hoc releases, considerable progress was achieved in restructuring financial liabilities. Particularly in cooperation with the major shareholders CAMKAN Invest S.a.r.l. and alpha capital management GmbH, due to fixed interest and loan waivers current liabilities were reduced from TEUR 8.702 in 2008 to TEUR 4.988, thereof TEUR 1.936 subordinated loan liabilities.
The above financial effects improve the group equity per September 30, 2009 to TEUR -2.729 (December 31, 2008 TEUR -5.654).
Overall, the restructuring and stabilization of the november group has been successfully continued through the 3rd quarter of 2009. Especially the very positive development of the operating results of PROGEN Biotechnik GmbH confirm the activities of the Management Board to focus on operative growth of the remaining companies of the november group.
In total, the above results in an earning per share (EPS) in the amount of EUR 0.62.
November 11, 2009 the relocation of company headquarters to Cologne was recorded in the Company Registry.
The complete consolidated quarterly report per September 30, 2009 is published under Reports.
end of announcement euro adhoc
Further inquiry note:
Christoph Schmitz
Leiter Finanzen, Controlling
Tel.: +49 (0) 221- 820 05 20 -24
E-Mail: schmitz@november.de
Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade